References
- Slichenmyer W. J., Rowinsky E. K., Donehower R. C., Kaufman S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 1993; 85(4)271–291, [PUBMED], [INFOTRIEVE]
- Barton-Burke M. Gemcitabine: a pharmacological and clinical overview. Cancer Nurs. Apr., 1999; 22(2)176–183, [CSA], [CROSSREF]
- Murren J., Kraut E., Balcerzak S., Gams R., Galloway S., Schultz M., Masters G., Chang A. Phase II trial of topotecan and cyclophoamide (CY) with G-CSF in high-risk small cell lung cancer (SCLC). ASCO Proc. 1998; 17(1907)495a, [CSA]
- Raefsky E. L., Hainsworth J. D., Burris H. A., Hopkins L. G., Greco F. A. Phase I trial of topotecan, paclitaxel, and carboplatin in patients with advanced refractory malignancies. ASCO Proc. 1998; 17(1920)498a, [CSA]
- Long G. S., Sinibaldi V. J., O'Reilly S., Carducci M. A., Grochow L. B., Reyno L., Enger C., Eisenberger M. A. A Phase I and pharmacologic study of suramin (S) and topotecan (T) in patients (PTS) with hormone refractory prostate cancer (HRPC). ASCO Proc. 1998; 17(948)247a, [CSA]
- Sandler A., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., Mattson K., Manegold C., Palmer M. C., Gregor A., Nguyen B., Niyikiza C., Einhorn L. H. Phase III study of cisplatin with or without gemcitabine (G) in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. Jan., 2000; 18(1)122–130, [PUBMED], [INFOTRIEVE]
- Nagourney R. A., Link J., Kunkel L., Evans S. Phase II trial of cisplatin (CDDP) and gemcitabine (DFDC) in heavily pretreated breast cancer. ASCO Proc. 1998; 17(619)161a
- Madajewicz S., Viola M., Hentschel P., Burns P., Caruso R., Fiore J., Fried M., Malhotra H., Ostrow S., Sugarman S., Viola M. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies. J. Clin. Oncol. 2000; 18(20)3553–3557, [PUBMED], [INFOTRIEVE]
- Hitt R., Castellano, Garcia-Carbonero R., Pena M., Brandariz A., Millan J. M., Alvarez Vincent J. J., Cortes Funes H. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann. Oncol. 1998; 9(12)1347–1349, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Greggi S., Salerno M., D'Agostino G., Fernandina G., Lorusso D., Manzione L., Mancuso S., Scambia G. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer. Oncology 2001; 60: 19–23, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sun W., Stevenson J. P., Gallagher M., Giantonio B., Algazy K., Haller D., Vaughn D., Raskay B. J., O'Dwyer P. J. A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 2001; 92(2)414–419, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rinaldi D., Lormand N., Brierre J., Cole J., Barnes B., Fontenot F., Buller E., Rainey J. A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3). Cancer Investig. 2001; 19(5)467–474, [CSA], [CROSSREF]
- Gridelli C. Topotecan, a recent discovery and prospects for treating tumors of the lung. Tumor 1999; 85(6 Suppl. 1)S16–S22, [CSA]
- Steward W. P., Dunlop D. J. New drugs in the treatment of non-small cell lung cancer. Ann. Oncol. 1995; 6(Suppl. 1)49–54, [PUBMED], [INFOTRIEVE]
- Ferrigno D., Buccheri G. Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?. Lung Cancer 2000; 29: 91–104, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gridelli C., Cigolari S., Gallo C., Manzione L., Ianniello G. P., Frontini L., Ferrau F., Robbiati S. F., Adamo V., Gasparini G., Novello S., Perone F. Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small cell lung cancer elderly patients: phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial. Lung Cancer 2001; 31(2–3)277–284, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gridelli C., Perrone F., Gallo C., Rossi A., Barletta E., Barzelloni M. l., Creazolla S., Gatani T., Fiore F., Guida C., Scognamiglio F. Single-agent gemcitabine as second-line treatment in patients with advanced non-small cell lung cancer (NSCLC): a phase II trial. Anticancer Res. 1999; 19(5C)4535–4538, [PUBMED], [INFOTRIEVE], [CSA]
- Bianco V., Di Girolamo B., Pignatelli E., Speranza I., Florio G., Gemma D., Girolami M., Vietri F., Marchei P. Gemcitabine as single agent therapy in advanced non-small cell lung cancer and quality of life in the elderly. Panminerva Med. 2001; 43(1)15–19, [PUBMED], [INFOTRIEVE], [CSA]